Prof. Robert Zorec University of Ljubljana, Slovenia
4 Talks
Biography
Robert Zorec is Professor of Pathophysiology at the University of Ljubljana, Faculty of Medicine, a Member of Academia Europaea (London), Slovenian Academy of Sciences and Arts (est. 1693 as Academia Operosorum), The Norwegian Academy of Science and Letters, and has been a Member of the Committee for Advanced Therapies at the European Medicine’s Agency (London), 2009-2013. Studying vesicle trafficking mechanisms in pituitary cells, plant cells, hepatocytes, adipocytes, taste cells, neurons and glia, his work revealed the nature of these universal mechanisms, which underlie the evolutionary invention of eukaryotic cells. In 2000 established the Cell Engineering Lab at Celica BIOMEDICAL (becoming Director in 2006), a concessionaire for research funded by the government of Slovenia. Based on membrane fusion experiments, his lab has developed autologous advanced cell-based medicines (electrofused autologous dendritic and tumor cells, i.e.HybriCure® technology for immunohybridoma-based immunotherapy), clinically tested (EudraCT # 2012-005498-29) in castration resistant prostate cancer patients with encouraging results.
To use this function, you need to be signed in
with a personal account.
If you already have a personal account, please
login here.
Otherwise you may sign up now
for a personal account.
Cookies and Privacy
We use cookies, and similar tools, to improve the way this site functions, to
track browsing patterns and enable marketing. For more information read our
cookie policy and
privacy policy.
Some types of cookies can be disabled by you but doing so may adversely
affect functionality. Please see below:
(always on)
If you block these cookies or set alerts in your browser parts
of the website will not work.
Cookies that provide enhanced functionality and personalisation. If not
allowed functionality may be impaired.
Cookies that count and track visits and on website activity enabling us
to organise the website to optimise the experience of users. They may be
blocked without immediate adverse effect.